InflaRx (NASDAQ:IFRX) Price Target Raised to $10.00 at Guggenheim

InflaRx (NASDAQ:IFRX) had its target price hoisted by Guggenheim from $7.00 to $10.00 in a report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Stock Performance

InflaRx stock opened at $1.24 on Wednesday. InflaRx has a one year low of $1.13 and a one year high of $2.82. The stock has a fifty day moving average of $1.88 and a 200 day moving average of $1.90. The stock has a market cap of $83.24 million, a PE ratio of -1.15 and a beta of 1.98.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. As a group, sell-side analysts predict that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of InflaRx during the 4th quarter valued at approximately $1,576,000. Commonwealth Equity Services LLC lifted its holdings in InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after purchasing an additional 19,000 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after purchasing an additional 11,900 shares during the period. Walleye Capital LLC purchased a new stake in shares of InflaRx in the fourth quarter worth $51,000. Finally, Two Sigma Securities LLC bought a new stake in shares of InflaRx during the 4th quarter valued at $28,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.